Greenwich LifeSciences, Inc. (GLSI)
NASDAQ: GLSI · IEX Real-Time Price · USD
13.98
-0.47 (-3.25%)
May 17, 2024, 4:30 PM EDT - Market closed
Company Description
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers.
Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018.
Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Greenwich LifeSciences, Inc.
| Country | United States |
| Founded | 2006 |
| IPO Date | Sep 25, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Snehal S. Patel |
Contact Details
Address: 3992 Bluebonnet Dr, Building 14 Stafford, Texas 77477 United States | |
| Phone | 203-434-3290 |
| Website | greenwichlifesciences.com |
Stock Details
| Ticker Symbol | GLSI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.75 |
| CIK Code | 0001799788 |
| CUSIP Number | 396879108 |
| ISIN Number | US3968791083 |
| Employer ID | 20-5473709 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Snehal S. Patel | Chief Executive Officer, Chief Financial Officer and Director |
| Eric Rothe | Founder and Independent Director |
| Dr. Frank Joseph Daugherty M.D. | Chief Medical Officer and Director |
| Dr. Jaye L. Thompson Ph.D. | Vice President Clinical and Regulatory Affairs |
| Dr. Christine T. Fischette Ph.D. | Vice President of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Apr 15, 2024 | 10-K | Annual Report |
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Feb 20, 2024 | 8-K | Current Report |
| Feb 14, 2024 | 8-K | Current Report |
| Dec 15, 2023 | 8-K | Current Report |
| Oct 25, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 25, 2023 | ARS | Filing |
| Oct 25, 2023 | DEF 14A | Other definitive proxy statements |
| Oct 19, 2023 | 10-Q | Quarterly Report |